dc.contributor.author | Brand, A | |
dc.contributor.author | O'Toole, B | |
dc.contributor.author | Muthukumar, M | |
dc.contributor.author | Matthews, J | |
dc.contributor.author | Kiff, F | |
dc.contributor.author | Shaw, N | |
dc.contributor.author | Wilson, ECF | |
dc.contributor.author | Digby-Bell, J | |
dc.contributor.author | Crathorne, L | |
dc.contributor.author | Melendez-Torres, GJ | |
dc.date.accessioned | 2022-10-17T10:17:38Z | |
dc.date.issued | 2022-10-05 | |
dc.date.updated | 2022-10-14T20:33:53Z | |
dc.description.abstract | Executive Summary: This summary provides a brief overview of the key issues identified by the evidence review group (ERG) as being potentially important for decision-making. It also includes the ERG’s preferred assumptions and the resulting incremental cost-effectiveness ratios (ICERs). • Section 1.1 provides an overview of the key issues and the differences in the assumptions of the company and the ERG in economic analysis. • Section 1.2 provides an overview of key model outcomes and the modelling assumptions that have the greatest effect on the ICER. • Sections 1.3 to 1.5 explain the key issues in more detail. Background information on the condition, technology and evidence and information on non-key issues are in the main ERG report. • Sections 1.6 and 1.7 provide an overview of the ERG’s preferred base case and sensitivity analyses undertaken by the ERG. All issues identified represent the ERG’s view, not the opinion of the National Institute for Health and Care Excellence (NICE). | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/131290 | |
dc.identifier | ORCID: 0000-0002-3743-1627 (Matthews, Justin) | |
dc.identifier | ScopusID: 55425519800 | 57115710200 | 57213035081 (Matthews, Justin) | |
dc.language.iso | en | en_GB |
dc.publisher | Peninsula Technology Assessment Group (PenTAG), University of Exeter | en_GB |
dc.rights | © 2022 , PenTAG, University of Exeter. Copyright is retained by Celgene (a Bristol-Myers Squibb company) for tables and figures copied and/or adapted from the company submission and other submitted company documents. | en_GB |
dc.title | Ozanimod for treating moderately to severely active ulcerative colitis [ID3841] A Single Technology Appraisal | en_GB |
dc.type | Report | en_GB |
dc.date.available | 2022-10-17T10:17:38Z | |
dc.description | This report was commissioned by the NIHR Systematic Reviews Programme as project number 13/54/43 | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-10-05 | |
rioxxterms.type | Technical Report | en_GB |
refterms.dateFCD | 2022-10-17T10:14:27Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-10-17T10:17:47Z | |